Forward, Together
The acquisition of Cytognos accelerates the expansion of the BD portfolio in blood cancer diagnostics, immune assessment tests and informatics, by addressing the needs of clinicians and care providers to better understand the immune system, immune response and minimal residual disease (MRD).
Cytognos' key products increase BD diagnostic and research solutions for certain types of cancers that use flow cytometry as the primary means of discovery, diagnosis and understanding, including lymphoma, leukaemia and multiple myeloma.
The synergy of Cytognos and BD for Onco-haematology
Onco-haematology at Cytognos
At Cytognos, we are committed to bringing solutions to improve patient care and laboratory efficiency by next generation flow cytometry.
Cytognos offers scientific-based solutions to monitoring patients affected by some forms of leukemia, alerting clinicians if the disease is still present or if there is a sign of recurrence. This is a key element of the patient care continuum, helping clinicians in the timely treatment of patients.
Onco-haematology at BD
Built on the research and validation work of the EuroFlow™ Consortium on the characterisation of hematological malignancies for improved accurate diagnosis1, BD brings the standardisation of leukaemia and lymphoma immunophenotyping one step forward, improving laboratory efficiency and enabling reliability and accuracy of results for clinical decisions and ultimately patient outcomes2,3.
The synergy of Cytognos and BD for Immunology
Immunology at Cytognos
Cytognos offers a highly sensitive method for the screening of suspected primary immunodeficiencies (PIDs) by flow cytometry4.
Most patients with PIDs present common clinical manifestations as the result of immune dysfunction. Cytognos offers solutions aiding to the screening of alterations possibly associated with immunodeficiencies or other immune system disorders, to orient towards diagnosis and further treatment4.
Immunology at BD
BD offers a portfolio for identifying and quantifying T, B and NK lymphocyte subsets for the immunological assessment of normal individuals and patients having, or suspected of having, secondary immune deficiency.
Individuals with human immunodeficiency virus (HIV) typically exhibit a steady decrease in CD3+CD4+ lymphocyte counts as the infection progresses5. While those with COVID-19 disease typically exhibit a decrease in CD3+CD4+ and/or CD3+CD8+ lymphocyte counts with increasing disease severity5.
Discover our new clinical flow cytometry family!
Combined solutions to better serve clinicians and their patients in the fields of onco-haematology and immunology.
Talk to a representative if you want to know more about Cytognos joining BD
*Required fields